106 related articles for article (PubMed ID: 14993385)
1. Protein origami: therapeutic rescue of misfolded gene products.
Conn PM; Leaños-Miranda A; Janovick JA
Mol Interv; 2002 Sep; 2(5):308-16. PubMed ID: 14993385
[TBL] [Abstract][Full Text] [Related]
2. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo.
Conn PM; Ulloa-Aguirre A; Ito J; Janovick JA
Pharmacol Rev; 2007 Sep; 59(3):225-50. PubMed ID: 17878512
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the human gonadotropin-releasing hormone receptor: insights into receptor biology and function.
Bédécarrats GY; Kaiser UB
Semin Reprod Med; 2007 Sep; 25(5):368-78. PubMed ID: 17710733
[TBL] [Abstract][Full Text] [Related]
4. Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism.
Ulloa-Aguirre A; Janovick JA; Leaños-Miranda A; Conn PM
Hum Reprod Update; 2004; 10(2):177-92. PubMed ID: 15073146
[TBL] [Abstract][Full Text] [Related]
5. Drug development and the cellular quality control system.
Conn PM; Janovick JA
Trends Pharmacol Sci; 2009 May; 30(5):228-33. PubMed ID: 19307028
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease.
Ulloa-Aguirre A; Janovick JA; Brothers SP; Conn PM
Traffic; 2004 Nov; 5(11):821-37. PubMed ID: 15479448
[TBL] [Abstract][Full Text] [Related]
7. Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors.
Schwieger I; Lautz K; Krause E; Rosenthal W; Wiesner B; Hermosilla R
Mol Pharmacol; 2008 Mar; 73(3):697-708. PubMed ID: 18048502
[TBL] [Abstract][Full Text] [Related]
8. Misrouted cell surface receptors as a novel disease aetiology and potential therapeutic target: the case of hypogonadotropic hypogonadism due to gonadotropin-releasing hormone resistance.
Ulloa-Aguirre A; Janovick JA; Leaños-Miranda A; Conn PM
Expert Opin Ther Targets; 2003 Apr; 7(2):175-85. PubMed ID: 12667096
[TBL] [Abstract][Full Text] [Related]
9. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target.
Janovick JA; Maya-Nunez G; Conn PM
J Clin Endocrinol Metab; 2002 Jul; 87(7):3255-62. PubMed ID: 12107234
[TBL] [Abstract][Full Text] [Related]
10. G-protein-coupled receptor trafficking: understanding the chemical basis of health and disease.
Ulloa-Aguirre A; Janovick JA; Miranda AL; Conn PM
ACS Chem Biol; 2006 Nov; 1(10):631-8. PubMed ID: 17168568
[TBL] [Abstract][Full Text] [Related]
11. The hydrophobic amino acid residues in the membrane-proximal C tail of the G protein-coupled vasopressin V2 receptor are necessary for transport-competent receptor folding.
Thielen A; Oueslati M; Hermosilla R; Krause G; Oksche A; Rosenthal W; Schülein R
FEBS Lett; 2005 Sep; 579(23):5227-35. PubMed ID: 16162341
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
13. Charged residues of the conserved DRY triplet of the vasopressin V1a receptor provide molecular determinants for cell surface delivery and internalization.
Hawtin SR
Mol Pharmacol; 2005 Oct; 68(4):1172-82. PubMed ID: 16049168
[TBL] [Abstract][Full Text] [Related]
14. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
[TBL] [Abstract][Full Text] [Related]
15. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway.
Hermosilla R; Oueslati M; Donalies U; Schönenberger E; Krause E; Oksche A; Rosenthal W; Schülein R
Traffic; 2004 Dec; 5(12):993-1005. PubMed ID: 15522100
[TBL] [Abstract][Full Text] [Related]
16. Structure of the third intracellular loop of the vasopressin V2 receptor and conformational changes upon binding to gC1qR.
Bellot G; Granier S; Bourguet W; Seyer R; Rahmeh R; Mouillac B; Pascal R; Mendre C; Déméné H
J Mol Biol; 2009 May; 388(3):491-507. PubMed ID: 19285506
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic rescue of misfolded/mistrafficked mutants: automation-friendly high-throughput assays for identification of pharmacoperone drugs of GPCRs.
Smithson DC; Janovick JA; Conn PM
Methods Enzymol; 2013; 521():3-16. PubMed ID: 23351731
[TBL] [Abstract][Full Text] [Related]
18. GnRH receptor and GPR54 inactivation in isolated gonadotropic deficiency.
de Roux N
Best Pract Res Clin Endocrinol Metab; 2006 Dec; 20(4):515-28. PubMed ID: 17161329
[TBL] [Abstract][Full Text] [Related]
19. Pro7.33(303) of the human GnRH receptor regulates selective binding of mammalian GnRH.
Fromme BJ; Katz AA; Millar RP; Flanagan CA
Mol Cell Endocrinol; 2004 Apr; 219(1-2):47-59. PubMed ID: 15149726
[TBL] [Abstract][Full Text] [Related]
20. Calnexin regulated gonadotropin-releasing hormone receptor plasma membrane expression.
Brothers SP; Janovick JA; Conn PM
J Mol Endocrinol; 2006 Dec; 37(3):479-88. PubMed ID: 17170088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
